ESGO 2026 Insights: The Future of Ovarian Cancer Care

n

The 27th European Congress on Gynaecological Oncology (ESGO 2026) recently concluded in Copenhagen, leaving the oncology community with a renewed sense of “innovation in the wind.” For those treating or living with ovarian cancer, the takeaways were clear: we are moving away from “one-size-fits-all” chemotherapy and toward a future defined by precision surgery, molecular targeting, and smarter immunotherapy.

Here is a roundup of the practice-changing insights reshaping the landscape of ovarian cancer care.

1. A New Era for Platinum-Resistant Ovarian Cancer (PROC)

Historically, patients whose cancer returned within six months of platinum-based chemotherapy had very limited options. ESGO 2026 highlighted two major breakthroughs for this group:

• The KEYNOTE-B96 Success: New data confirmed the FDA approval of pembrolizumab (Keytruda) plus paclitaxel for PD-L1-positive, platinum-resistant disease. This combination significantly extended both progression-free survival (PFS) and overall survival, marking a historic win for immunotherapy in a space where it has previously struggled.

• Elenagen—The DNA-Based Disruptor: One of the most talked-about presentations involved Elenagen, an investigational DNA-based therapy. When combined with gemcitabine, it nearly doubled median overall survival (from 13 months to over 25 months) by reshaping the tumor microenvironment and “training” the immune system to attack cancer-specific targets.

2. The 2026 Multidisciplinary Guidelines

ESGO officially introduced its updated Ovarian Cancer Management Guidelines, the first comprehensive update since 2017. The new standards emphasize:

• Centralization of Care: The message was uncompromising—ovarian cancer surgery should only be performed in specialized centers of excellence. Data continues to show that complete tumor resection (no visible disease left behind) is the single most important prognostic factor for survival.

• Molecular-Guided Strategy: Maintenance therapy (like PARP inhibitors) is no longer a “maybe.” It is now the standard of care, with guidelines providing clearer algorithms for sequencing these drugs based on a patient’s HRD (Homologous Recombination Deficiency) status.

3. Precision Surgery & AI Integration

Surgery is becoming less about “how much we can remove” and more about “how precisely we can remove it.”

• Dual-Tracer Mapping: Research presented showed that dual-tracer sentinel lymph node mapping achieved 100% sensitivity for detecting spread, allowing surgeons to avoid radical, life-altering surgeries when they aren’t necessary.

• The Rise of AI: From the POLARIX model (which predicts genetic mutations with 97% accuracy) to AI-enhanced imaging that helps surgeons identify unresectable disease before the first incision, technology is becoming a co-pilot in the operating room.

4. Innovations in Recurrence: Radspherin and Radiotherapy

For patients with peritoneal recurrence, the RAD-18-001 study presented 24-month data on Radspherin. This “alpha-emitting” therapy is injected directly into the abdominal cavity after surgery to mop up microscopic cancer cells. At the recommended dose, only 1 in 10 patients saw their cancer return in the treated area—a massive leap in local disease control.

Furthermore, experts highlighted the growing role of Stereotactic Body Radiotherapy (SBRT) for “oligometastatic” disease (when cancer returns in only 1–5 spots). For patients who aren’t fit for a second surgery, targeted radiation is proving to be a highly effective, less invasive alternative.

5. Prioritizing the “Human” Side: Quality of Life (QoL)

A major theme throughout the congress was that “living longer” isn’t enough—patients must “live well.” New patient resources, such as the Olivia Digital Pathway, were showcased and designed to help women navigate the emotional and physical complexities of the disease. ESGO 2026 underscored that symptom management, psychological support, and preserving sexual function are as critical to the “success” of a treatment as the clinical data itself.

The Bottom Line

The “Wind of Innovation” at ESGO 2026 has brought a new level of optimism. We are entering an era where ovarian cancer is treated as a collection of distinct molecular diseases rather than a single condition. With the integration of AI, the success of new immunotherapy combinations, and the refinement of surgical techniques, the future of care is becoming more personalized—and more hopeful—than ever before.